Results in The Journal of American Dental Association showed the non-opioid combination provided superior pain relief during ...

Tonix Pharmaceuticals (NASDAQ: TNXP) has appointed Gary Ainsworth as Vice President, market Access, as the company prepares for the potential FDA approval of TNX-102 SL, a non-opioid analgesic for ...

Inservice education prepared pharmacists for discussions with physicians about opioid analgesics. Phase 3 centered on an automatic interchange from meperidine to an equianalgesic dose of morphine ...

Medically reviewed by Lindsay Cook, PharmD Vicodin (hydrocodone-acetaminophen) and Percocet (oxycodone-acetaminophen) are ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in ...

Approximately $50.0 million of net revenue from sales of LUMRYZ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients ...

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid ...

A combination of acetaminophen (Tylenol) and ibuprofen (Advil, Motrin) controls pain after wisdom tooth removal better than ...

Their pain relief mechanism however differentiates them from narcotic analgesics. NSAIDs can relieve pain locally and centrally inhibiting prostaglandin synthesis. [11] In spite of the beneficial ...